tirzepatide ckd trial Interplay of Chronic Kidney Disease and the Effects of Tirzepatide in Patients With Heart Failure, Preserved Ejection Fraction, and Obesity: The SUMMIT Trial

Effects of tirzepatide versus insulin glargine on kidney outcomes in type 2 diabetes in the SURPASS-4 trial: post-hoc analysis of an open-label, randomised, phase 3 trial

22.22

★★★★☆4.8 (126)

Renal effects and safety of tirzepatide in subjects with and without diabetes: A systematic review and meta-analysis

24.82

★★★★★4.9 (98)

Join a trial on tirzepatide for kidney disease | Headlands Research - AMCR Institute posted on the topic

20.56

★★★★★5.0 (157)

Tirzepatide (Zepbound) showed improved kidney function in obese patients with both chronic kidney disease and #heartfailure with preserved ejection fraction, highlighting its potential to address this high-risk patient population. Read more: https

25.75

★★★★★4.7 (84)

Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes

22.38

★★★★★4.9 (203)

At #ACC25, Dr. Milton Packer and colleagues present a new secondary analysis from the SUMMIT trial evaluating the effect of tirzepatide in patients with obesity, #HFpEF, and CKD. The trial demonstrated that #

25.38

★★★★★5.0 (176)

Effects of Renal Impairment on the Pharmacokinetics of the Dual GIP and GLP-1 Receptor Agonist Tirzepatide | Clinical Pharmacokinetics

20.18

★★★★★4.8 (132)